OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Cancer is 77. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Enhancing childhood cancer targetability	738
An oncolytic circular RNA therapy	599
Considering molecular alterations as pan-cancer tissue-agnostic targets	442
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	408
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	355
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	352
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	322
Gut decisions in CAR T cell therapy	314
MALAT1 protects dormant tumor cells from immune elimination	269
Breaking frontiers with multidisciplinary cancer research	254
A low-coverage liquid biopsy for lung cancer	209
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study	205
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	203
A macrophage-activated abscopal effect	181
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	167
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	162
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	162
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	153
Shooting for multiplexed pathology with Orion	148
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	148
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	144
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial	144
The cGAS–STING pathway and cancer	140
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	140
Expanding the options for KRAS inhibition	137

Palmitate oxidation drives a pro-metastatic post-translational modification	137
A molecular glue halts RAS–MAPK signaling	134
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	134
The importance of being generous	131
Bone marrow progenitor-like cells against leukemia cure	127
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial	123
Shaping the microenvironment in peritoneal metastases	122
Determinants of resistance and response to melanoma therapy	120
Advancing therapeutics in small-cell lung cancer	115
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	115
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	114
Stress granules shape metabolic reprogramming and drug resistance	114
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	113
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	113
Impact of context-dependent autophagy states on tumor progression	113
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	111
Sarcoma ecotypes determine immunotherapy benefit	110
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	110
Antibody avidity meets multiple myeloma	107
Key insights from ESMO Congress 2025	103
Inflammation meets translation in AML	101
Innate immunity drives epithelial cell plasticity during prostate tumor formation	101
Thriving in diverse ecosystems	101
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	97
Evolving landscape of nasopharyngeal carcinoma therapy	94
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	94
A comeback for checkpoint inhibition in multiple myeloma	93
A tumor-derived metabolite primes the leptomeningeal pre-metastatic niche	93
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial	93
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	92
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	92
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	91
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	91
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	91
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	90
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	90
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	90
Cycling back to folate metabolism in cancer	89
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	89
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	89
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	88
Multimodal data integration improves immunotherapy response prediction	86
Immunotargeting of a recurrent AML-specific neoantigen	85
Dual inhibition of EGFR and PI3K with a single drug	85
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	84
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	84
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	82
Radioligand cancer therapy comes to the fore	82
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	82
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	81

Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	80
Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics	78
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	77
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	77